Drug Search Results
More Filters [+]

HB-0025

Alternative Names: hb-0025, hb 0025, hb0025
Latest Update: 2024-01-24
Latest Update Note: Clinical Trial Update

Product Description

Huabo Biopharm Co., Ltd. is developing HB-0025 as a treatment for solid tumors. (Sourced from: http://www.huabobio.com/en/product.html)

Mechanisms of Action: PD-L1 Inhibitor,VEGF Antagonist

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Huabo Biopharm Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HB-0025

Countries in Clinic: China, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Endometrial Cancer|Kidney Cancer|Renal Cell Carcinoma

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HB0025-0101

P2

Recruiting

Kidney Cancer|Renal Cell Carcinoma

2025-01-30

57%

CTR20222862

P2

Not yet recruiting

Kidney Cancer

None

CTR20210604

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

CTR20230223

P2

Not yet recruiting

Endometrial Cancer

None

Recent News Events

Date

Type

Title